Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 12/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.55 |
| ▸ | YES1 | P07947 | 1/20 | 0.55 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 10/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 10/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201113 | 0.81 | PIK3CA (0.47) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL10201098 | 0.77 | PGK1 (0.49) | KDM4E | |
| SCHEMBL31052622 | 0.77 | PARP2 (0.48) | MAPK1AURKBYES1MAPTKDM4E | |
| SCHEMBL7916858 | 0.75 | CYP1A2 (0.52) | MAPTMEN1KMT2A | |
| SCHEMBL3790900 | 0.73 | MAPK1 (0.48) | MAPK1AURKBYES1HIPK1PIK3CA | |
| SCHEMBL2553395 | 0.73 | MAPK1 (0.49) | MAPK1AURKBYES1HIPK1PIK3CA | |
| SCHEMBL1552411 | 0.73 | CHRNB2 (0.51) | MAPK1AURKBPIK3CAMAPK8MAPK9 | |
| SCHEMBL20565743 | 0.72 | POLB (0.52) | MAPTKDM4EMEN1KMT2A | |
| SCHEMBL1932174 | 0.71 | MAPK1 (1.00) | MAPK1AURKBYES1HIPK1PIK3CA | |
| SCHEMBL7916840 | 0.71 | ALDH1A1 (0.42) | MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | MAPK1 878/4885AURKB 1778/4885YES1 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.